Overview

Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension

Status:
Completed
Trial end date:
2014-11-14
Target enrollment:
Participant gender:
Summary
The objective of this Phase 2 study is to evaluate whether the Bimatoprost Ocular Insert is non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
Phase:
Phase 2
Details
Lead Sponsor:
ForSight Vision5, Inc.
Treatments:
Bimatoprost
Ophthalmic Solutions
Pharmaceutical Solutions
Timolol